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INTRODUCTION
Within the past decade, progress in immuno -hematology has
extended beyond the study of the erythrocyte. The demonstration
of antibodies to red cells in some cases of acquired hemolytic
anemia and in erythroblastosis fetalis defined the hypothetical
existence of analogous phenomena for leucocytes and platelets.
Advancements in immunologic technique have elevated the importance
of immune bodies in the etiology of several cytopenic blood dis
orders.
Extensive research has been done to elucidate the presence
and nature of an anti-platelet factor in the serum of patients
with thrombocytopenic purpura. Evidence of such a serum factor
has been found in three varieties of this disease: 1) the
idiopathic type, 2) the congenital type, and 3) the drug hyper
sensitivity type (e.g., quinidine and sedormid). They have been
grouped together as the immunologic thrombocytopenic purpuras.
(The drug reaction variety does not include thrombocytopenia due
to direct megakaryocyte damage by agents such as benzol, nitro
gen mustards, and the anti-metabolite drugs, which can produce
bone marrow aplasia of all blood cell elements. ) Early workers
called this anti-platelet serum factor an antibody. The term
"platelet antibody" has been used by many investigators (and in
this study) for the sake of conveniencej however, the serum factor
has not always been proved to be a true, specific antibody, nor
has the platelet been proved to be the specific antigenic stimu
lus.
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The aim of this study is 1) to review the immunologic research
in thrombocytopenia, and 2) to investigate the sera of patients with
idiopathic thrombocytopenic purpura for platelet antibody by means
of the technique of immune adherence.
Part I - A REVIEW
0
Idiopathic Thrombocytopenic Purpura (ITP):
Clinically ITP is a disease of unknown etiology, with a
variable onset and course, which may be marked by spontaneous re
missions and relapses (72). It is characterized by petechiae and/or
ecchymoses in the skin as well as by bleeding from mucous membranes
and into various tissues. There is evidence that some cases have an
antecedent infection or allergy. ITP is most common in children and
young adults, with females predominating. Clinically the patient
feels and looks well, except if excessive blood loss (30). The
spleen is palpable only in 20 per cent of patients, while the liver
and lymph nodes are not enlarged. The platelet count is reduced,
the bleeding time prolonged, the coagulation time is essentially
normal, the clot is nonretractile (i.e. there are sufficient plate
lets for coagulation, but not for clot retraction), prothrombin
consumption is reduced, the thromboplastin generation time is in
creased (7), and the Rurnpel-Leeds tourniquet test is positive.
There is no anemia except when blood loss occurs, and any leukocyte
changes are insignificant. Platelets may be both large and small,
with some deeply stained. Bleeding usually occurs when the plate
let count is below 60,000 per mm3. Bone marrow examination reveals
the megakaryocytes to be young, large and small, and about twice as
numerous as in the normal marrow. However, platelet production is
seen in only 10 to 20 per cent of megakaryocytes compared to 70 per
cent in the normal (72).
The course of ITP may be classified as acute or chronic, but
no sharp deliniation exists. The acute cases show very low platelet
h
count, with norms! platelet morphology. In children
there is a
slight increase in the percent of eosinophils and lymphocytes in
the WBC differential. Without treatment complete improvement occurs
from within a few days to a few months. The disease is self limit
ing, and usually no other spontaneous attacks occur. In chronic
cases, the platelet count is not as low as in the acute variety, but
the platelets are often large, bizarre, and irregular. The WBC
differential is normal. Chronic patients are more commonly women
in whom remissions and exacerbations occur. The remissions are
not likely to be complete. About 20 per cent of acute cases go on
to the chronic stage (58). Splenectomy is the only chance of cure
in chronic ITP, whereas the acute patient may be supported by
transfusion, and/or have his recovery hastened by steroid therapy.
Acute cases that do not recover in a few months are also treated
by splenectomy.
The symptomatology of congenital thrombocytopenic purpura in
the newborn is identical to that of ITP. Most cases recover
spontaneously in 1 to 3 weeks. However, there is a fatality rate
of 20 per cent due to hemorrhage resulting from the Usual trauma
of normal delivery.
Thrombocytopenic purpura due to drug hypersensitivity can be
distinguished from acute ITP only by the fact that the former is
precipitated by the sensitized patient being administered the drug
(such as quinidine or sedormid). Treatment requires only the
cessation of the drug in question. (72, 28).
Another type of probable immunologic thrombocytopenia is that
which may develop following multiple bank-blood transfusions over
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a short period of time. The platelet count may remain decreased for
several days (72).
One of the first indications that thrombocytopenic purpura
might be related to a blood factor that destroyed platelets was
the experiment of Bedson {$) in 1922. The administration of guinea
pig heterologous anti-platelet serum to normal guinea pigs produced
marked thrombocytopenia and damaged the capillary epithelium. Similar
work has been repeated recently by Mattison (L>0) ; anti-dog platelet
rabbit serum caused immediate thrombocytopenia, but no purpura, when
injected into normal dogs.
Splenectomy was first performed to treat ITP in 1916. In 1925
Frank suggested that ITP was due to an abnormal splenic secretion,
and therefore splenectomy produced a favorable result by removing
this secretion (3). The same year Bedson and Johnson (6) prepared
heterologous antisera against guinea pig lymph gland extract as
well as against endothelial phagocytes from peritoneum, bone marrow
and spleen. The anti -lymph and anti-peritoneal phagocyte sera were
without effect on platelets in vivo, whereas the anti-bone marrow
and anti-spleen sera removed the platelets almost completely from
the circulation of normal guinea pigs. They concluded that this
finding indicated the presence of platelet antibody, which in turn
was produced by platelet antigen present in the bone marrow and
spleen.
Troland and Lee (66) in 1938 reported that splenic extract
from a patient with ITP produced thrombocytopenic purpura when in
jected intravenously into rabbits. There were some confirmations
of this observation (hi), but the majority of similar experiments
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failed (6U). At this same time Torrioli (65) reported that splenic
extracts from patients with ITP inhibited the growth of megakaryocytes
in tissue cultures. Thus, two early theories were developed; one
stated that ITP was primarily a disorder of increased platelet
destruction in the circulation, while the other claimed that de
creased platelet production in the megakaryocytes was responsible for
the disease (30). These two theories were partially united in 1939,
when Tocantins demonstrated that serum from a patient with ITP in
jected into normal dogs increased platelet destruction and decreased
platelet production in the same animal (63).
In 19U9, Evans et al. (21) confirmed an observation made by
Widal in 1907 that some patients with acquired hemolytic anemia had
persistent neutropenia and thrombocytopenia. They therefore suggest
ed that since acquired hemolytic anemia is due to a demonstrable
agglutinin, the thrombocytopenia and granulocytopenia might have a
similar basis. Evans et al (22) succeeded in demonstrating in vitro
a thrombocyte agglutinating factor.
In 1951, Harrington et al. (31) in St. Louis observed that the
transfusion of blood from patients with ITP into normal individuals
often caused thrombocytopenia and occasionally acute purpura in the
recipient. Blood from 26 cases of ITP produced thrombocytopenia in
16 normal, compatible recipients (32). The decrease in platelet
count was apparent in 30 to 60 minute s; maximal in 2 to 3 hours, and
persisted for k to 7 days. The anti-platelet factor remained active
when the ITP blood was stored up to 9 days at 5° C and up to 8 days
at 25° C. In Boston, Stefanini et al. (60) reported similar experi
ments in 1953, and added that degenerative changes of the megakaryo
cytes were noted in the bone marrow of normal recipients, who had
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acquired thrombocytopenia as a result of being transfused with plasma
from patients with ITP. Thrombocytopenia rarely occurred in normal
recipients when plasma from patients with acute ITP was used. It is
noteworthy that transfusion of blood from 2 of Harrington's patients
produced thrombocytopenia in the recipients, both before and after
the donors had undergone splenectomy, even though in each case the
platelet count had returned to normal after the operation (31).
Stefanini concurred with this observation in his study, and also
reported that the thrombocytopenic effect of plasma from one patient
with chronic ITP was of shorter duration in splenectomized recipients
than in normal ones. This was interpreted as indicating that the
spleen may be responsible for the removal of "sensitized" platelets (60).
Studies of the survival of transfused platelets from normal donors
also appear to support the idea that the platelets in ITP are destroyed
abnormally fast. The normal life span of a platelet is 8 to 9 days
(72). Stefanini 's laboratory showed that in thrombocytopenia due to
chronic HP, bone marrow replacement ; as with leukemia, metastatic
carcinoma, etc, and toxic hypoplasia, the platelets survive for about
2 to k days (57, 59); but in acute cases of ITP with very low plate
let counts, the donor's platelets often disappear from the patient's
circulation in 30 minutes to 21; hours (56). He suggested that the
first group with 2 to h day platelet survival may represent decreased
platelet production as the chief pathologic mechanism of the thrombo
cytopenia; whereas the very short survival in acute ITP may represent
rapid platelet destruction in the pathogenesis of this disorder.
With multiple transfusions, the survival of platelets becomes pro
gressively decreased with repeated transfusion into normal or thrombo-
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cytopenic recipients. This is considered to be due to the develop
ment of platelet iso-agglutinins, which exert an adverse effect on
the transfused platelets (59).
Stefanini and Harrington have also performed extensive in vitro
experiments to detect an anti-platelet factor in the blood of patients
with ITP. Both used a simple agglutination technique. A drop of
serum (Harrington) or plasma (Stefanini) was added to a drop of
platelet suspension, and the mixture observed under the microscope.
If the platelets agglutinated sufficiently the test was positive for
anti-platelet factor.
In 1953, Harrington et al (32) demonstrated platelet agglutinins
in the sera of 21 of 31 cases of ITP. The following year (27), an
enlarged series was reported in which 50 of 72 patients with ITP
(70 per cent) had sera positive for agglutinins against normal
platelets from compatible donors. The incidence of antibody de
tection did not appear to be influenced by age, sex or whether the
illness was acute or chronic. 6 per cent of normal control sera also
agglutinated the normal platelets of compatible donors. Auto-ag-
glutinins (i.e., for their own platelets) were found in the sera of
two-thirds of the 27 patients on whom the procedure could be per
formed. Auto-agglutinins were more easily detected if the patients'
remission phase platelets were tested against their thrombopenic
phase serum. Harrington's technique contained the following re
finements: all glassware in contact with platelets was coated with
silicone; ethylenediamine tetraacetic acid disodium salt (EDTA Na2;
"Sequestrene Na2n; or "Disodium Ver senate") was the anticoagulant;
platelets were not washed, but remained in their own plasma; the test
9
sera were prepared by allowing fresh sterile blood samples to clot
in uncoated glass tubes and to incubate at 37°C. for 2k hours; serum
was then removed and heated for 30 minutes at 56°C to inactivate, com
plement and remove coagulation factors; the platelets and test sera
were mixed and incubated overnight at 5°C; the mixture was poured onto
a slide which was mechanically oscillated for 30 minutes prior to
being read.
In 1953, Stefanini et al (62), found platelet iso-agglutinins
in the plasma of 22 of 78 cases of ITP (28 per cent). In 1955, (5W
he reported an enlarged series of these patients, in which only 3k
of 119 plasmas were positive for iso-agglutinins (29 per cent). Age
and sex were not factors, but the duration of the disease did in
fluence the results in this study (5U). Of the 119 patients, 68 had
chronic ITP and 51 had the acute disease. Iso-agglutinins were found
in 30 of the chronic cases (kk per cent), and in only k of the acute
group (8 per cent). It was possible to study the plasma of 62
patients for the presence of auto-agglutinins: 20 were positive
(32 per cent). However, 18 of 32 chronic cases (56 per cent) had
auto-agglutinins compared to only 2 positives (7 per cent) in the
30 plasma samples from patients with acute HP tested for auto-ag
glutinins. In general, the autoagglutinins were found in plasma that
had been demonstrated to contain iso-agglutinins as well. Since the
incidence of agglutinins in acute ITP was in the range of false
positives (6 per cent) obtained with normal control plasma, Stefanini
and Dameshek (58) concluded that platelet agglutinins could be
demonstrated only in chronic cases of ITP with about one-half the
frequency of Harrington's results. The effect of splenectomy on the
presence of agglutinins was also tested (62). In 12 of 15 chronic
1C
cases with agglutinins, splenectomy failed to cause any diminution
in the titer of the iso-agglutinin, although the patients' platelet
counts had returned to normal after the operation. However, in 5
of 9 chronic cases who also had auto-agglutinins against their own
platelets, the auto-agglutinin disappeared after splenectomy, although
the iso-agglutinin titer for platelets from normal individuals re
mained unchanged. Treatment with ACTH or cortisone caused the ag
glutinin to become weaker or disappear in several acute cases that
improved with this therapy (56, 29).
Stefanini *s agglutination technique (58) also employed silicone-
coated glassware, EDTA Na2, and unwashed platelets suspended in their
own plasma. The blood to be tested was collected in EDTA so that
plasma instead of serum would be obtained by centrifugation. However,
to inhibit the normal clotting mechanism, which otherwise might cause
non-specific clumping of the platelets, the test plasmas were passed
through a cation exchange resin to remove calcium ions. Centrifuga-
tions were all done at U°C. In Stefanini *s technique, the platelet
suspension and test plasma are combined and incubated at room temper
ature for 60 minutes. The test tubes are then centrifuged at 500 rpm
for 2 minutes to re suspend the platelets prior to examination under
the microscope for agglutination. (The chelating agent, EDTA Na^,
acts as an anticoagulant by binding calcium ions. Thus, EDTA will
prevent complement fixation which requires calcium.)
Both groups of investigators compared the results of therapy of
ITP with the results of previous tests for platelet agglutinins. In
1957, Harrington (28) again reported an agglutinin incidence of
about 75 per cent in a series of 200 cases of ITP; 77 of these patients
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were eventually treated with splenectomy. Of the patients with
a
positive test for platelet agglutinins, 83 per cent (72 of Qk cases)
received a favorable response from splenectomy; while of the patients
without demonstrable agglutinins, only 22 per cent (5 of 23 cases)
were benefited by operation. Contrary to this result, Stefanini and
Dameshek (58) found no corellation between the response to splenectomy
and the presence of agglutinins in a smaller series of cases.
The results of the transfusion experiments and the demonstrations
of platelet agglutinins appeared to show clearly that a considerable
portion of cases of ITP have a circulating anti-platelet factor, and
it was considered the probable cause of the thrombocytopenia. How
ever, the problem was more complicated. Both Harrington's and
Stefanini 's groups found platelet agglutinins in the blood of some
patients who previously had been transfused or pregnant, but who had
never suffered from ITP (3). Blood from 2 of 19 normal persons who
had had transfusions caused thrombocytopenia when given by Harrington
to normal recipients (32). Ackroyd (3) considers these findings to
be important in assessing the significance of anti-platelet factors
in the blood of patients with UP, because many of these patients were
treated by transfusions (especially during the years before cortisone
was generally available). His analysis of the 31 cases reported by
Harrington in 1953 showed that all but 9 had received transfusions
or had been pregnant. Of these 9, 5 had anti-platelet agglutinins.
Stefanini et al (60) also described platelet agglutinins in the plasma
of normal individuals who had been transfused or pregnant. His group
noted 2 patients who had developed immune platelet agglutinins follow
ing repeated transfusion. In these patients transfusion of "compatible"
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platelets (as judged by agglutination tests) produced no greater
rise in the platelet counts than did transfusion of "incompatible"
platelets; the platelets in each case being removed from the cir
culation very rapidly. They also found that transfusion of plasma
from these two patients into both "compatible" and "incompatible"
recipients caused comparable and striking falls in their platelet
counts. Furthermore, Harrington observed that transfused platelets
only rarely survive for a normal time in cases of ITP; even in those
with no demonstrable platelet agglutinins (27).
Several investigators question the significance of the thrombo
cytopenia produced by the transfusion of blood from patients with
ITP into normal recipients (3). In 1952, Stefanini and Chatterjea
(55) and Wilson et al (71) observed that the transfusion of blood,
plasma or serum from healthy individuals to normal recipients also
caused a striking fall in the platelet count. The former group ob
served thrombocytopenia in 32 of 3^> recipients of normal blood in
their experiments; the mean fall was over 50 per cent of the
original platelet count. In 1953, Stefanini (57) reported that
the transfusion of plasma from Ik in a group of 35 patients with
ITP caused a significant fall in the platelet count in normal re
cipients, but in 12 this could be distinguished only in duration
from the thrombocytopenia which frequently followed the transfusion
of normal plasma to normal recipients.
To further the confusion, Ackroyd in his review (3) noted the
astonishing observation of Wilson et al "that if blood or plasma
from UP cases is transfused to normal recipients and their platelets
are then estimated, no fall in the platelet count will be observed
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if the platelets are counted in citrated venous blood by the direct
method of Tocantins, although a fall will be observed if they are
counted in citrated capillary blood by the indirect method of
Damashek used by Harrington and Stefanini" (70).
The studies thus far described make it very difficult to judge
to what extent and how often ITP is due to the presence of an anti
platelet factor in the blood stream, and whether or not this factor
is a true antibody formed in response to a platelet antigen.
Another factor that makes evaluation of platelet agglutinins ex
tremely difficult is that some workers who have tried to demonstrate
agglutinins in the plasma of patients with ITP have either failed to
do so or have obtained unreproducible results (3, Ilc3) • Stefanini
(60) emphasized the technical difficulties by noting that negative
agglutination tests would at times become positive by having an
optimal proportion between platelet concentration and agglutination
titer. The technique of platelet agglutination has been criticized
for its lack of specificity and sensitivity to low "antibody" titers.
For a positive test the amount of agglutination that must occur is
small. The phenomenon of in vitro platelet clumping or aggregation
is a major technical problem. It is non-specific and can give rise
to spurious results, which have caused several workers to be dis
satisfied with the agglutination technique-.
Nonetheless, Dausset in Paris has championed the agglutination
technique for several years. His method is similar to that of
Harrington and Stefanini: i.e., silicone-coated glassware, EDTA anti
coagulant, and centrifugation at k°C. A major difference is that the
platelets were washed 3 times with saline, and re suspended in saline.
Ik
It was presumed that washing removed EDTA and any plasma proteins
that surrounded the platelets. Dausset believes that EDTA inhibits
platelet agglutination. The washed platelet suspension must give a
negative result when tested immediately after preparation against a
normal serum to be used in further tests. In 195U, he introduced a
mechanical agitator (lU). The reagents were combined on glass
slides and incubated for 1-1/2 hours in a moist chamber using con
stant agitation. In 1957, Dausset (15) presented his results after
testing the sera of patients with a variety of diseases. With in
cubation at ii°C, platelet agglutinins were found in the following
percentages: normal individuals 1 per cent, acute ITP 31 per cent,
chronic ITP 17 per cent, lupus erythematosus Ijl per cent, cirrhosis
35 per cent, and symptomatic thrombocytopenia (from leukemia,
Hodgkin's disease, lymphosarcoma, hemolytic anemia, etc.) 12 per
cent. Dausset named these, "cold" platelet agglutinins, and stated
that they were non-specific, independent of complement, and adsorbed
onto the platelets. He next proceeded to study platelet agglutination
at 37°C, and the interfering problem of platelet clumping. In a
recent report in I960, Dausset (16) presented his results and his
opinion of platelet aggregation (i.e. clumping) vs. platelet ag
glutination. He states that "aggregation is probably the first
stage of blood clotting, and requires traces of thrombin and a
dialysable factor. Traces of thrombin are present in serum speci
mens separated from the clot. The phenomenon is not inhibited by
heating sera to 56°C. or by passing them through a cation exchange
resin. Absorption by barium sulfate or tricalcium phosphate will
remove the thrombin, and so inhibit the aggregation." On the other
i:.
hand, "agglutination is provoked only by certain pathologic sera,
and is not inhibited by heating to 56°C, , by passing it through r.
cation-exchange resin, or by absorption with barium sulfate or tri-
calcium phosphate. It is probably an immunologic phenomenon". On the
basis of these ideas, Dausset modified his agglutination technique as
follows: Coagulation factors responsible for platelet clumping were
removed by 1) late separation of the serur.i from the clot, 2) heating
the serum for 30 minutes at 56°to destroy complement, and 3) absorp
tion by barium sulfate. Platelets compatible with the ABO group of
the serum to be tested were used. The platelets were washed at It C,
to remove EDTA and surrounding proteins, and then heated at 56°C. for
16 seconds. Dausset believes that heating the platelets als^ prevents
clumping by destroying adherent protein clotting factors; however,
there was an optimal time of 16 seconds. Heating for a few seconds
longer inhibited true agglutination. The platelet-serum mixtures
were incubated for 90 minutes in depressed-center glass slides, with
circular agitation as before, but this time at 37°C. Using this re
cent method, Dausset (16) found platelet agglutinins active at 37°C.
in 87 out of 1633 pathologic sera from patients with a variety of
diseases; 70 per cent of the positive sera were from women. In the
control group, 2 of 252 normal sera contained platelet agglutinins;
these 2 positive control sera were both from multiparous women. Out
of the 87 positives, 79 were from a group of 6I4I patients who had
been transfused in their past medical history. The incidence of
these platelet "warm" iso-agglutinins increased from 3 per cent in
patients who had 1 to 3 blood transfusions to kl per cent in those
who had received 100 to 200 units of blood. With one exception,
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platelet "warm" agglutinins were not found in the sera from 116
patients with ITP.
The techniques and results of platelet agglutination by
Harrington, Stefanini and Dausset are summarized and compared in
Table 1.
The contradictory results obtained by various workers indicate
that false reactions may occur very frequently, due to the poorly
understood tendency of platelets to aggregate in clumps, independent
of an antigen-antibody reaction. The most rigorous study of the
cause and prevention of non-specific platelet clumping in vitro and
of the various modifications of the agglutination technique has
recently been done by Lundevall in Oslo. In 1958, his results were
reported in an extensive monograph on platelet serology (39). He
found that when platelets were collected, blood coagulation must be
prevented to avoid clumping. The best anticoagulant was EDTA Na2;
it also preserved platelet morphology. In his experiments the slide
method with constant agitation of Dausset was used, because it does
not require transfer of the mixture for microscopic reading and
agitation provides maximum collisions between particles. It was
demonstrated that clumping did not occur after repeated washings of
the platelets with saline, contrary to the opinion of Stefanini et al
(60). A surface active wetting agent (detergent) "Triton WR-1339"
was added to the washed platelet-saline suspension. (This agent and
a similar one "Tween 80" in dilute solution effectively prevented
the adhesion of platelets to foreign surfaces such as glassware.)
Washing did not alter the morphology of the platelets. Hjort (33)
claims that the removal of adsorbed coagulation factors from the
Table 1
PLATELET AGGLUTINATION TECHNIQUES
HARRINGTON STEFANINI DAUSSET DAUSSET
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platelet surface by washing alters the antigenic structure of the
platelets. Lundevall did not run simultaneous experiments with
washed vs unwashed platelets, and therefore Hjort's point had not
been disproved. Lundevall found no difference in the clumping
ability of platelets after they had been washed in silicon-coated
vs plain glass tubes. Siliconized tubes were used because, after
centrifugation, it was easier to re suspend the platelets in them
than when plain glass was employed.
Lundevall showed that in crystalline solutions "platelet clump-
ing"occurred at pH below U.5 (adjusted with HC1); at pH about 6 no
clumping took place. In saline containing NaOH, and in tris-
hydroxymethyl aminomethane ("Sigma") buffer solutions at pH between
7 and 9, platelet clumping occurred. The more alkaline the reaction,
the stronger was the clumping. Platelets from different individuals
showed varying ability to form clumps in this pH area. In the
presence of citrate or EDTA no clumping took place between pH 7 and
9, while the addition of calcium ions enhanced the clumping. Pure
saline (pH about 6) containing calcium did not clump platelets. The
clumping at pH between 7 and 9 was strongest at room temperature.
Storage of unwashed platelets in their own EDTA-containing plasma
enhanced their ability to form clumps at pH between 7 and 9. Washed
platelets gradually lost their clumping ability when stored in Tri
ton-saline. Augmentation of the ionic strength in the medium caused
inhibition of the platelet clumping. Heating to 37° reduced the
clumping ability of the platelets, and heating to 1|2° for 30 minutes
entirely abolished this ability." Nelson (U6) has shown that clumping
will not occur in "Veronal" buffer at pH of 6 to 7.
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Lundevall (39) demonstrated the following reactions of plate
lets in serum. The addition of normal serum caused non-specific
platelet clumping, but only at serum dilutions of l/l6 or less. The
clumping was proportional to the concentration of platelets in the
mixture. Clumping of the mixture was increased also by the addition
of reduced hemoglobin. The platelet clumping ability of serum disap
peared with lowering the pH to between 6 and 7. "The addition to the
serum of l/lO volume of a 2 per cent solution of EDTA caused its
platelet clumping ability to disappear. The addition to serum of
citrate and oxalate even in considerable amounts does not ensure the
elimination of platelet clumping. Passage of serum through a column
of cation exchange resin reduced its platelet clumping ability; sub
sequent addition of calcium to the serum restored this ability.
"
Removal of calcium by dialysis of the serum against saline had the
same effect. Serum in which protein coagulation factors were re
moved by adsorption with barium sulfate also had a pronounced ability
to clump platelets when calcium was added. Sera from patients lack
ing certain coagulation factors (i.e., anti-hemophilic globulin, pro-
accelerin and proconvertin) clumped platelets as well as normal sera.
"Thrombin alone or in the presence of calcium did not clump washed
platelets." Whether any of the coagulation factors besides calcium
in some way influence serum's ability to clump platelets was not
investigated. "Heating the serum to 100° caused a slight decrease
in its platelet clumping ability. This decrease was compensated by
the addition of calcium to the serum." Pre-absorption of normal
serum with platelets did not reduce its non-specific clumping ability.
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Thus from Lundevall 's results a technique of platelet ag
glutination that is optimum for the inhibition of platelet clump
ing should include: centrifugation at ii°C, washed and then quick-
heated platelets, pH between 6 and 7, pre-heated serum, and the
removal of calcium ions. The simplest method to remove calcium is
the addition to serum of EDTA to a final concentration of 2 mg. per
ml. Lundevall' s refinements are therefore practically identical to
those used by Dausset.
Lundevall has not studied a series of sera from patients with
ITP for the presence of platelet agglutinins. He has studied sera
from a heterogeneous group of 978 hospital patients and blood donors.
"7 per cent of the sera contained "cold" agglutinins active below
10°C. At room temperature agglutinins were present in 3 per cent of
the sera. No sera were found with "warm" agglutinins active at 37°C.
When agglutinins were demonstrated, they were independent of hematolo
gical or other lmown diseases, and independent of earlier transfusions
and pregnancies. Sera from some additional patients, shown to contain
platelet antibodies by other methods, did not contain platelet ag
glutinins.
" Lundevall concluded that the platelet agglutination
test is therefore of minor clinical interest (39).
In another modification in technique, Harrington and Stefanini
treated platelets with various enzymes (e.g., papain and pepsin) to
enhance their agglutinability by platelet antibody. A somewhat in
creased frequency of positive agglutination reactions was found by
the use of platelets treated in this way. Dausset (15) warned against
the use of enzymes, as this may lead to false positive platelet ag
glutination. Harrington (32) also found that the addition of calcium
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and magnesium ions and fresh horse serum could increase the per
centage of positive tests.
Dissatisfaction with the platelet agglutination test has caused
several workers to try other techniques of antibody detection. In 195U,
Fluckiger et al (23) adapted the Direct Coombs antiglobulin test for
the demonstration of platelet agglutinins. "Platelets from the patient
to be tested are washed and added to anti-human globulin rabbit serum.
Agglutination of the platelets occurs if the platelets are coated with
human platelet antibody in vivo.
"
Fluckiger found positive reactions
in 3 out of 5 patients with ITP; 30 normal individuals showed nega
tive tests. Stefanini (60), Harrington (27), and Dausset (Ik) re
ported single cases of ITP with a positive test, but in general found
positive results with platelets from 3 patients without thrombocyto
penia. The red cells of these patients gave a positive Direct Coombs
test. One difficulty with this test is that it is difficult to obtain
platelets from some patients with ITP who have a very low platelet
count. Lundevall (39) believes that the test is of interest because
it is the only in vitro method that can detect platelet antibodies
when they are not free in the serum; this is analogous to some cases
of immunologic hemolytic anemia. Also this test should identify
thrombocytopenia that may be due to the development of i so-antibodies
following blood transfusions.
The indirect Coombs test has also been used to detect platelet
antibody (39). Platelets are incubated with the patients serum.
The platelets are then washed and suspended in Coombs' anti -human
globulin rabbit serum. Agglutination will occur, provided the plate
lets are coated with human antibody. This antibody has been called
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an "incomplete" or "non-agglutinating" antibody. In 195k, van
Loghem and Hart (39) used this test on 57 sera; many were suspected
to contain platelet antibodies, but no positive reactions were
found. They concluded that this method, which is very sensitive
for the study of red cell serology, was of little value in platelet
work. Jaeger -Draafsel et al (35) examined 9k0 blood bank sera by an
agglutination method and the indirect Coombs test. Platelet anti
bodies were detected in 17 per cent of the sera. Of these anti
bodies, 6.1; per cent were only agglutinating, 8.0 per cent were only
non-agglutinating, and 2.6 per cent were both. Several workers re
garded this test as too complicated. Coombs et al (10) warned
against non-specific positive reactions, which may occur in a heter
ologous system.
In a further search for a better technique, Kissmeyer-Nielsen
(36) introduced a method in 1953 based upon the adsorption of plate
let extract proteins on to the surface of tannic acid treated
erythrocytes. When suspended in a potent anti-platelet serum, the
red cells agglutinated. However, he obtained disappointing results
with this hemagglutination method, using serum from ITP patients.
Other investigators showed that the method gave false positive results,
and discarded it.
'
In 1955, Moulinier (1;2) introduced an anti-globulin consumption
test to detect non-agglutinating platelet antibody. In this technique,
normal platelets are incubated with the human serum to be tested.
The platelets are then washed and suspended in anti -globulin serum
of known strength. After a short incubation, the platelets are spun
down, and the supernatant serum is tested for anti-globulin activity
with red cells coated with non-agglutinating human antibody. Any
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reduction of this activity is believed to be caused by a platelet
antibody in the test serum. Using papain treated platelets, he
found that the sera of 15 patients with ITP all contained platelet
antibody, whereas, the sera of 70 normal individuals contained none.
Lundevall (39) also used the anti-globulin consumption test in
his investigations. He assayed the amount of anti -globulin con-
summed more easily and more precisely by the method of Jones, than
by the titration method of Moulinier. The Jones method consists of
measuring the time from the mixing of anti-globulin serum and anti
body-coated red cells to the start of agglutination, Lundevall found
that some anti-globulin was consummed by platelets treated with
normal sera or saline, and therefore he subtracted this control
value from that of the test serum. In the sera of 30 normal in
dividuals no non-agglutinating platelet antibodies were found. Such
antibodies were detected in the sera of 8 patients. These patients
were of 3 categories: 2 polytransfused patients with normal platelet
counts; 3 patients with secondary thrombocytopenia, who had been
transfused repeatedly; and 3 thrombocytopenic patients, who had not
been transfused or pregnant (one with ITP). Normal platelets,
labelled with radioactive chromate, had a shortened survival time
when transfused to 7 of these patients (39). In general, the anti
globulin consumption test is too time-consuming and complicated for
use in a large series.
In 1953, Tullis (67) described a complement fixation method in
which lysis of platelets occurred in the presence of complement and
platelet antibody. The test sera were absorbed with barium sulfate
to inactivate prothrombin, plasma thromboplastin, and prothrombin-
conversion accelorator factor, and decalcified by passage through a
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cation exchange resin. Untreated serum from platelet donors (blood
type 0, Eh negative) provided the complement in this homologous
system. Minute quantities of washed platelets (0.07 ml), patient's
serum (0,15 ml) and complement (0,05 ml of a l/32 dilution) were
incubated at 37°C after mixture on a silicone-coated glass slide. A
cover-slip was applied and platelet counts were done initially and
after kB and 90 minutes. Any reduction of the platelet count was
thought to be caused by lysis, and hence evidence of the presence
of platelet antibody. A UO per cent reduction in the number of plate
lets was the criterion for a positive test. His results were reported
in 1956 (68). A positive test was demonstrated with the sera from
57 per cent of 96 cases of ITP; as well as in 66 per cent of 21 cases
with thrombocytopenia due to hypersplenism. All tests were negative
when the sera from a mixed group of 200 normal individuals and patients
with various other hematologic diseases were tested. Sera from 127
patients with secondary thrombocytopenia (e.g., from bone marrow re
placement in leukemia and metastatic carcinoma; and from toxic and
radiation bone marrow hypoplasia) were also negative. He concluded
that patients with secondary thrombocytopenia do not have a circulating
platelet antibody. He considers this test to be important clinically
to help distinguish the thrombocytopenic purpuras with antibody (ITP
and hypersplenism) which respond to steroid therapy and splenectomy,
from cases of secondary thrombocytopenia, which require platelet
transfusions. Tullis (68) also found that treatment of ITP often de
creased and sometimes eliminated the demonstrable platelet antibody,
as was noted when spontaneous remissions occurred. However, the anti
body titer could not be used as a criterion of clinics! response. The
decrease in antibody with treatment was often temporary; the reap-
pearance of antibody months later with a recurrence of t.oromb^-
cytopenia was not unusual. With treatment, reversal of th- test to
negative was rapid, and sometiiries preceded clinical improvement by
several days. This was unexpected since the half-life of preformed
gamma globulin is 20 to 30 days. Incubation of positive serum with
cortisone had no effect on the test. Tullis suggested that corti
sone releases inhibition of platelet production, as well as decreases
antibody formation. He concluded that no prognostic implications could
be draxm from the presence or absence of platelet antibody before
starting therapy; 65 per cent of patients with or without antibody
improved, while one half of the unimproved patients had a positive
antibody test before the initiation of therapy.
Other researchers have used the platelet lysis method. Cruz
(11 ) recorded the degree of lysis by a turbidimetric method. He
tested the potency of anti-platelet serum made by immunizing rabbits
with dog platelets; guinea pig complement was employed. Jamra in
his experiments measured platelet lysis by recording the volume of
sedimented platelets in a "thrombocytocrit" (39). Lysis methods
depend on the presence of complement, which is active only in the
presence of calcium and magnesium ions. Lundevall (39) noted that
since calcium ions enhance the non-specific clumping of platelets,
platelet counts could never be very accurate.
DeNicola et al (18) have demonstrated complement fixation in
animal experiments with the standard technique of measuring the
hemolysis of sensitized red cells to detect previous complement utili
zation in the antigen-antibody system tested. Complement fixation
by guinea pig platelets in anti-platelet rabbit serum took place at
serum dilutions of 1/700. (ivon-immunized rabbit serum and guinea
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pig platelets did not fix complement.) The same platelets and
anti-sera showed a positive agglutination test up to a serum dilu
tion of 1/128, which demonstrates the superiority of complement f ide
ation to detect platelet antibody in this heterologous experimental
situation. Lundevall (39) has not employed complement fixation
tests because of the calcium ions-platelet clumping problem
mentioned above.
Other methods have been used to a lesser degree by European
workers in platelet antibody investigations. They include: pre
cipitation of lyzed platelets, immuno-electrophoresis, electron-
microscopic observation of platelet morphology, reduction in clot
retraction, and reduction in thromboplastin formation (39). In
general, they have been non-specific and unsuccessful.
The most recent platelet antibody detection technique is the
mixed cell agglutination method of Coombs in England, described in
1956 (10). Red cells coated with non-agglutinating red cell anti
body (i.e., "sensitized erythrocytes") and platelets coated with
non-agglutinating platelet antibody are mixed in a suspension. The
addition of anti-human globulin serum to the mixture will provoke
mixed agglutination of red cells and platelets provided both anti
bodies are of the incomplete (i.e. non-agglutinating) type. The
platelet coating is done by incubating washed platelets with the
serum to be tested, followed by re-washing the platelets. Clotting
factors were removed from the test sera by barium sulfate absorp
tion. Serum from 6 patients suspected of having platelet antibody
was tested (8): 2 post-transfusion patients' sera gave positive
tests, but serum from k patients with ITP were all negative for
this method. Coombs (8) stated that "the most likely explanation
would seem to be that, in these negative cases, the antibody, if
indeed it is an antibody, is combining with an antigen not situated
at the cell surface."
Thus, there is discrepancy as to the existence of platelet anti
body in idiopathic thrombocytopenic purpura. To summarize, positive
tests for antibody have been performed by Harrington (agglutination
method); Stefanini (agglutination method, but only in chronic ITP);
Fluckiger (direct anti-globulinmethod for non-agglutinating antibody);
Moulinier (anti -globulin consumption technique for non-agglutinating
antibody); and Tullis (platelet lysis by complement). On the other
hand, platelet antibody has not been demonstrated in the sera of
patients with ITP by: Dausset (agglutination method at 37°C. for "warm"
agglutinins) ; Stefanini (agglutination method, in acute ITP) ; van
Loghem (indirect anti-globulin method for non-agglutinating antibody) ;
and Coombs (mixed cell indirect anti-globulin method for non-ag
glutinating antibody). Quantitatively, the evidence seems to be in
favor of the existence of some type of anti-platelet factor in the
sera of some patients with ITP. All of the investigators in this
field do agree on one point. Namely, none of the methods hitherto
described are completely satisfactory. The distribution of identical
serum samples to the laboratories of several of the investigators
mentioned produced discrepancies in antibody demonstration by the
different techniques. Sera from diseases with increased globulin
production (e.g., lupus erythematosus, cirrhosis, macroglobulinemia,
and multiple myeloma) at times gave false positive results.
In 1958, Stefanini and Mele (6l) compared their agglutination
technique with a complement fixation method on the same sera from




Diagnosis # of cases Agglutination vs Comp. Fix.
Acute ITP 27 k 3
Chronic ITP 32 19 17
Lupus erythematosus 18 Ik 9
Liver disease 113 29 1
The agglutination test gave a greater number of positive results.
There was close correlation with ITP. If a serum was negative by
agglutination, it was never positive by complement fixation.
Lundevall notes the reason for dissatisfaction with all avail
able techniques. "The specificity of the methods is doubtful, and
they involve a great deal of work, a fact which prevents their wide
application and makes controls difficult" (39). The search for
better immunologic techniques continues.
Congenital Thrombocytopenic Purpura
In conjunction with studies of platelet antibody in ITP, re
ports have appeared of cases of transient thrombocytopenic purpura
in infants of mothers who had or had had ITP. This has been sug
gestive evidence for the transmission of an anti-platelet factor
across the placenta from the maternal to the fetal circulation in
this extremely rare disease.
Harrington et al (32) investigated 8 infants with brief
neonatal purpura born to 3 mothers each of whom had undergone
splenectomy for ITP prior to 7 of the 8 pregnancies. Two mothers
had recovered after the operation, and had normal platelet counts;
the third had improved only moderately. All 3 mothers had platelet
agglutinins, but in only 1 child (not the one born prior to
splenectomy) could agglutinins be demonstrated. In 1956, Har
rington (30) reported that passive transfer of platelet agglutinins
from mothers with ITP had been demonstrated in 23 of 21; infants with
congenital thrombocytopenic purpura. Four mothers with IIP, but no
agglutinins, all gave birth to normal babies.
Tullis (68) examined sera with his platelet lysis technique from
11 infants with this disorder and from their 10 mothers, who all had
had ITP at delivery or at some previous time. Seven of the infants
and 5 of the mothers had a positive test for platelet antibody.
However, there was no definite corollation between the presence of
the antibody in the mother and in her child, or vice-versa, partial
ly because of the small, size of the series. (Note: The techniques
of Harrington and Tullis have given the highest percentages of posi
tive results for anti-platelet factor in ITP. ) Other workers have
also found platelet agglutinins in the serum of both mother and baby
in similar cases (U9, 50, 69).
Harrington's group (32) also examined a case of transient
neonatal thrombocytopenic purpura, in which the mother had never
shown purpura or thrombocytopenia or received a transfusion. This
baby was her fourth pregnancy. Her plasma contained agglutinins
which acted on the infant's platelets, and on normal individual's
platelets, but not on her own. They concluded that "the mother
would seem to have been immunized to platelets by pregnancy, in
which case the thrombocytopenia in the infant may well have been
produced by a mechanism similar to that which causes the hemolytic
anemia in erythroblastosis fetalis". They have since observed 6
cases.
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Coombs' group (2U) reported a similar case this year. It
was the fourth pregnancy of this 2k year old woman, type 0, Rh
positive. She had received 2 pints of 0, positive blood during
each of 2 previous pregnancies, because of microcytic anemia.
The father's blood type was 0, Rh negative; the baby was type
0, Rh positive. A full term male was spontaneously delivered.
Thrombocytopenic purpura was present at birth, but remitted without
therapy in 1 week. The mother was completely normal. Coombs'
mixed cell anti-globulin test demonstrated the presence of non-ag
glutinating platelet antibody in the serum of the healthy mother.
The antibody was active against the platelets of the father and 10
normal persons, but not against those of the mother. Unfortunately,
the infant's serum was not tested. Furthermore the mother's serum
did not contain any demonstrable antibodies against the father's
red cells. Thus, the case was attributed to the sensitization of
the mother by previous pregnancy or blood transfusion, with the
subsequent development of antibodies which crossed the placenta,
and reacted with the platelets of the fetus.
Platelet Groups
In the study of platelet immunology in thrombopenic state,
work has been done to determine the antigenic nature of platelets
in normal individuals. The evidence for the existence of platelet
groups depends mainly on the observation that, if platelet rich
blood is transfused to patients with thrombocytopenia secondary to
aplastic anemia or bone marrow replacement, the platelets persist
in the circulation for 2 to 5 days, but with repeated transfusions
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the survival time of the platelets often becomes progressively
shorter (3). These findings suggest that antibodies develop
against the transfused platelets, and imply that there may be
platelet groups which do not correspond to the red cell groups,
since there was no evidence of erythrocyte incompatibility. Har
rington et al (32) using a platelet agglutination technique,
tested 110 platelet specimens with plasma samples from patients
who had had repeated transfusions for refractory anemia. Their
results indicated the existence of 12 platelet groups. Stefanini
et al (60) in a similar series of experiments, considered that
they could differentiate 6 platelet groups, 3 of which were con
firmed by agglutination-cross absorption tests.
Stefanini et al (60) have also claimed that 6 per cent of
normal plasma samples from healthy individuals, who have never
been pregnant nor transfused, contain platelet agglutinins. They
cross tested platelets and plasma from 215 individuals, and as a
result of over 55,000 agglutination tests they concluded that there
are two naturally occurring platelet agglutinins, from which they
deduce that there are probably k platelet groups. There was no ap
parent relationship between any of these platelet groups and the
red cell groups (60, 27). Gurevitch and Nelken (25) however, have
found that the platelet groups correspond with the ABO red cell
groups. They found that the strength of agglutination of the
platelets varied according to the titer of the grouping sera against
red cells. The titer of such sera against platelets could be re
duced by adsorption of the sera with red cells or platelets. Ag
glutination occurred best at k° to 6° C. They also found that
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adsorbed anti-A and anti-B could be eluted from their respective
type platelets. Dausset (lit) also found A- and E-sntigens in
platelets, as did Coombs and Bedford (9) with their mixed aggluti
nation method. They observed that the iso-antibodies for A and B
had greater affinity to red cells than to platelets.
Agreement is lacking in the case of the Rh antigens in plate
lets. Meyer and Moureau (39) claimed to have demonstrated D and
CDE respectively. However, Gurevitch and Nelken (26) using ag
glutination, absorption, elution, mixed cell agglutination, direct
and indirect anti -globulin tests and the anti-globulin consumption
test were not able to demonstrate conclusively the presence of Rh-
antigens in platelets. Recently, Dausset (17) reported that his
group had demonstrated Rh antigen D on platelets from Rh positive
red cell individuals by means of the anti-globulin consumption test.
Ashurst et al (k) have not found red cell antigens: M,N,
Lutheran", Lewisa, or Lewis in platelets.
Different results again demonstrates the need for better
techniques.
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Part II - EXPERIMENTAL STUDY
Because of the dissatisfaction with existing methods for the
demonstration of platelet antibody (as discussed in Part I), the
author selected to employ a relatively new immunologic technique:
immune -adherence (I-A). The phenomenon of immune-adherence was
described by Nelson in 1953 (kk) , and has since been studied by
his group in this institution (U5, 1*6). Recently, I-A has been
used successfully by Brody in this laboratory to test for several
antibodies. The aim of this study was to determine if immune-ad
herence would demonstrate the existence of a platelet antibody in
the serum of patients with idiopathic thrombocytopenic purpura.
IMMUNE-ADHERENCE
Immune -adherence is a specific immunological reaction wherein
particulate antigens sensitized with antibody and complement become
attached to the surface of human or monkey erythrocytes (kk). The
presence of antibodies against starch granules, bacteria and viruses
has been shown with this technique. A positive reaction can be
read grossly, since the adherence of antigen and red cells forms a
fine film across the bottom of the tube, whereas in a negative test
the red cells settle to form a dense "button". The test is also read
microscopicly under dark-field illumination. The red cells are first
lyzed by the addition of water; in a positive reaction several red
cells are seen linked together by antigen particles. Although I-A
is not a simple test, it is extremely sensitive. I-A permits the
detection of antibody concentrations as low as .01 to .005 micrograms
of antibody nitrogen per ml. of serum (1;6). This technique can be
used to titrate the activity of antibody or complement. Unlike com
plement fixation, complement in human serum is as active as guinea
pig complement in I-A. This technique is sensitive to much higher
dilutions of complement than is complement fixation. The use of
I-A in studies of human complement has demonstrated a definitive re
quirement for both calcium and magnesium ions (kS) , Thus EDTA will
inhibit I-A by its chelating action on these ions. It is curious
that only red cells from man and other primates will undergo immune-
adherence; guinea pig platelets instead of human erythrocytes have
been used as the indicator, successfully, by Brody.
MATERIALS AND METHODS
a) Alsever's Anticoagulant Solution
per 500 ml of solution: 10.0 gm glucose
li.O gm sodium citrate
2.1 gm sodium chloride
Adjust pH to 6,1 with 1.0 ml of 5 per cent citric acid. Refrigerate.
b) Storage Mixture
2 parts of Alsever's solution to 1 part whole blood.
Add 250 units of Penicillin per ml of Al sever 's-blood
mixture. Refrigerate.
c) Veronal Buffer
per 2000 ml of solution: 35.0 gm sodium chloride
5.75 gm 5,5 diethyl barbituric
acid
3.75 gm 5,5 sodium 5,5 diethyl
barbiturate
Dissolve barbituric acid in 500 ml hot distilled water.
Add other compounds and cool. Bring solution to 2000 ml with
distilled water. Refrigerate. pH 6.3; 5 times isotonic.
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d) Serum Albumin Veronal Buffer (SAVB)
per 1000 ml of solution: 200 ml Veronal buffer
2.5 ml calcium chloride (.03M)
1.5 ml magnesium sulfate (.15H)
1.0 gm bovine albumin (Gelatin)
Dissolve albumin in 100 ml hot distilled water.
Sterilize. Add other compounds. Bring volume of solution
to 1000 ml with distilled water. Refrigerate.
Freshly prepared twice per week. pH 7.3 to 7.1;
e) Platelets
Blood for platelets was obtained from normal individuals and
polycthemic patients. The blood type of the donor was not a con
sideration. The platelets were prepared according to Nelson (1;6).
Because a refrigerated centrifuge was not available, centrifugation
was done with large cups filled with crushed ice. The temperature
was a few degrees higher than the ideal 0°C. Plain glass syringes
and test tubes were used. Ten ml of whole blood was collected in
a syringe containing 10 ml of cold Alsever's anticoagulant solution.
The mixture was packed in crushed ice and centrifuged for 30
minutes at 600 rpm. It was necessary to stop the centrifuge every
10 minutes in order to replace the ice. The supernatant contained
platelets and plasma; it was diluted with 5 ml of Al severs and
washed 3 times by centrifugation in crushed ice at 2000 rpm for 20
minutes. Occasionally the platelets were clumped; in which case
they were either separated by vigorous agitation or discarded.
Alsever's was used for the washings. (It has been shown that
citrate anticoagulants do not completely eliminate clumping (20).
Clumping does not occur in EDTA Nag, but it could not be used because
it inhibits I-A.) The final deposit was resuspended in 3 to 5 nl.
of SAVB and centrifuged at u00 rpm for 5 minutes to remove the few
erythrocytes and the remaining clumps of platelets. The super-
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natant 2 per cent platelet-SAVB suspension was used as the par
ticulate antigen. It was considered unnecessary to standardize
the platelet concentration to 50 per cent transmittance on the
Beckman DU spectrophotometer at a wave length of 1;00 millimicrons,
as done by Nelson (1+6). Platelets were freshly prepared for each
day's experiment.
f) Test Serum
Blood was obtained from 10 patients with ITP. The blood was
allowed to clot, and the clot then removed. Remaining red cells
were removed by centrifugation. The serum was stored in stoppered
glass test tubes in the deep freeze, and thawed when needed. The
serum was not preheated or absorbed. When tested, serial .1:1
dilutions from l/2 to 1/128 were made using SAVB.
g) Complement
Pooled normal guinea pig serum (Carworth Farms) was stored in
the deep freeze, and used as a source of complement. Normal human
sera were used as complement in some protocols, when a homologous
system was tried. The complement was kept in an ice-bath between
thawing, and its addition to the mixture. During this time the
complement serum was absorbed with the same red cells used as the
indicator. When the same red cells were used for several days ex
periments, a large volume of complement was absorbed with these
red cells as follows. One ml of washed red cells was incubated
with 20 ml of guinea pig complement for 15 minutes in a 0°C ice-
bath. This mixture was centrifuged at 1800 rpm for 10 minutes in a
0°C. centrifuge. The serum was removed and again absorbed with red
cells and centrifuged as above. Any remaining red cells and cellular
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debre were removed by ultra-speed centrifugation of the serum at
11;, 000 rpm for 15 minutes at 0°C. The serum was divided into 1.6
ml aliquots, and frozen in individual tabes, ready for use. In
general, complement was diluted l/UO with SAVB.
h) Red Cells
Only type 0, Rh negative red cells were employed, in order to
avoid possible agglutination by red cell antibodies that may be
present in the test serum. Whole blood was collected in cold
Alsever's solution in a ratio of 1:2, and stored in the refrigerator.
New stock solutions were obtained every few weeks. To prepare the
red cells for use as the I-A indicator, 10 ml of the stock solution
was centrifuged at 3,000 rpm for 10 minutes at room temperature.
The plasma supernatant and as much of the buffy layer (white cells)
as possible were removed. The red cells were washed three times
with 5 ml of SAVB. One ml of the packed red cells was diluted 1:10
and then 2:8 to give a 2 per cent suspension of red cells in SAVB.
The suspension required slight adjustment so that exactly 1 ml
(hemolyzed with distilled water to a volume of 10 ml) gave an optical
density of .395 when examined at a wave length of 51*1 on the Beckman
DU spectrophotometer. The 2 per cent red cell suspension was
freshly prepared from the stock for each day's experiment.
i) Method
Except during incubation, all reagents were stored and mixed at
0°C. in an ice-bath. The test serum was diluted 1:1 up to 1/128.
Initially 5 ml test tubes were used, but later 5 ml screw-cap vials
were found to be more satisfactory. The vials were used for the
later, significant experiments. A tube (or vial) was labelled for
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each dilution, and 0.25 ml of each serum dilution was pipetted
into its appropriate tube. 0.25 ml of the platelet suspension was
added to each tube, followed by agitation to assure adequate mixing.
In some experiments more than one concentration of platelets was
used. Next, 0.50 ml of the l/l;0 complement serum was added, and
the tubes were again agitated. The mixture was incubated at 37°C.
for about 15 minutes. Then 0.10 ml of the 2 per cent standardized
red cells was added to all tubes, giving a total reaction volume of
1.1 ml. Mixing was assured, and the tubes were again incubated at
37°C. for kS minutes, with agitation after the first 15 minutes.
(The vials were placed horizontally on a vertical revolving wheel in
the incubator, and were thus slowly revolved throughout the incu
bation period.) For controls, mixtures were prepared that lacked:
1) complement, 2) test serum, 3) complement and test serum, and oc
casionally these same three categories and no platelets. The volume
in all tubes was brought up to 1.1 ml with SAVB.
The tubes must be read at the end of incubation. The vials did
not give a gross pattern but the tubes could be read directly. The
controls and negative tests formed a red cell button at the bottom;
a positive test was graded from 1 to 1; depending on its variance from
a button and its proximity to a fine film of adherent red cells. All
mixtures (tubes or vials) were lyzed with water and examined by dark-
field microscopy. In a positive test groups of red cell "ghosts" were
seen adhered together with platelets between them, bridging the red
cell surfaces; single red cells had several platelets adherent to
them. Adherent bacteria had to be distinguished from platelets.
The percentage of platelets adherent to red cells was not counted.
When tubes were used, the gross result occasionally looked positive,
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while the microscopic result was negative. The latter was con
sidered more reliable. When a positive test was seen, only a small
minority of the red cells and platelets were adherent to each other.
EXPERIMENTAL RESULTS
a) Guinea pig serum
In order to rule out the possibility of a heterologous plate-
Let antibody in guinea pig serum, it was tested for I-A. With
either human or guinea pig complement the tests were negative.
b) Anti-human platelet rabbit serum
A heterologous system provided a model for the demonstration
of platelet antibody with I-A. Two normal rabbits were immunized
with 1 ml of a human platelet suspension injected intravenously.
Two weeks later a second dose of platelets was given to each. Serum
samples were obtained a month later. All rabbit sera tested in I-A
were first absorbed with indicator red cells at 0°C. for 30 minutes
to remove any possible naturally occurring heterologous red cell ag
glutinins. The pre-immunication serum sample from both rabbits
was negative for I-A, using human and guinea pig complement.
Both post-immunization sera gave strongly positive tests with
both sources of complement. The titers (reciprocal of highest posi
tive dilution) ranged from 200 to U00. Thus I-A can detect an
induced heterologous platelet antibody. Post-immunization serum
which was also absorbed with human platelets at 0°C. for 30 minutes
no longer gave a positive test; pre -absorption removed the antibody.
This heterologous antibody was not inactivated by heating to 56°C for
30 minutes. It was not demonstrated in a serum sample obtained from
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the same rabbit several months 1-ter.
c) ITP serum
Serum samples were obtained from 10 patients with ITP seen
in this hospital. Samples were obtained from 7 during the early
(acute) phase of their disease. The remaining 3 had been previously
treated by splenectomy. Age and sex of the patients are noted in
Table 2. The 10 sera plus a sample from a normal control were
tested for immune -adherence. All tests were negative. It was con
cluded that these patients with ITP did not have an iso-antibody
for platelets in their sera.
d) Combination of I-A and the Indirect Coombs Test
Because several investigators have claimed that incomplete or
non-agglutinating antibodies are present in IIP and can be demon
strated by anti-globulin techniques (see Part I), the use of rabbit
anti -human globulin serum ("Coombs serum") was adapted into the
immune-adherence test, to detect "incomplete antibody" in the
patients' sera. Human platelets were absorbed with the test sera
at room temperature for 30 minutes, centrifuged at 1500 rpm for 5
minutes, washed twice with SAVB, and then re suspended in 2 ml of
SAVB. These coated or "sensitized" platelets were the antigen for
I-A. Commercially available Coombs anti-globulin serum (Ortho Co. )
was used as the "antibody" for I-A. It was used at full strength and
1:1 dilutions with SAVB. The 10 LTP sera and the control sera did
not show I-A when human complement was employed in this modified
technique. The post-immunization rabbit serum was also negative.
With guinea pig complement, this post-immunization rabbit serum was
ko
positive for I-A; the anti-globulin serum titer was 128. When the
UP sera were tested using guinea pig complement, 6 sera gave a
positive result. (See Table 2). The control serum was still nega
tive. The 6 positive sera all showed low anti-globulin titers of
k in their I-A reactions. The 3 post-splenectomy patients were in
the negative group. Sensitized platelets and test serum as the
"antibody" were run in I-A and gave negative results as anticipated.
These experiments indicate that there is a platelet coating globulin
in the serum of some patients with UP. Since it did not show immune-
adherence with platelets, this globulin was not considered to be a
true antibody for platelets.
DISCUSSION
The assumption that idiopathic thrombocytopenic purpura is
etiologically related to a circulating anti-platelet factor was
based on two types of clinical experiments. Plasma or serum from
a variable percentage of patients with UP produced thrombocyto
penia when injected into normal recipients; and platelets from
normal individuals survived only briefly on transfusion into most
patients. These experiments performed by Harrington et al and
Stefanini et al have been described and evaluated in Part I. The
numerous in vitro immunologic experiments with sera from patients
with ITP have supported the theory that an anti-platelet factor
exists in the serum of some patients with this disease, even though
the results of these experiments have been variable, often incon
clusive, and contradictory in different laboratories, (see Part I).
These discrepancies have caused widespread dissatisfaction with
the available immunologic techniques, but rarely with the hypothesis




Treatment^Patient Ag< f Sex Diagnosis Phase of Serum Dire 3t I-A Anti-globulin
abbib immunized with 6 weeks post-
Human C G.pig C Human C G.pig Q'
Healthy r Uoo Uoo 0 100
human platelets immunization
Steroids
DG 17 female acute ITP acute phase 0 0 0 k Spontaneous
remission.
IK 36 male acute ITP acute phase 0 0 0 h Steroids
Splenectomy^
3D 17 female acute ITP acute phase 0 0 0 k Steroids
Soon. re (dss.
MB 26 female acute ITP acute phase 0 0 0 0 Ster .ids
Splenectomy*
SP 23 male acute ITP acute phase 0 0 0 U Steroids
Splenectomy*
DM 15 male acute ITP acute phase 0 0 0 k Steroids
Splenectomy*
CS 60 female ITP po st- splenec tomy 0 0 0 0 none
AM U8 male ITP post-splenectomy 0 0 0 0 none
BB Ul female ITP post-splenectomy 0 0 0 0 none
JS ll male acute ITP &
hem. anemia
acute phase 0 0 0 k Steroids
Splenectomy*
MG 30 male control
- 0 0 0 0
# In general patients were given steroids during the acute ohase, when serum sample wan
obtained.
* These patients were not well controlled with steroids. Therefore they were treated
by splenectomy within a few months.
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by all. Nonetheless, the name "platelet antibody" has been as
signed to any UP serum that has demonstrated a positive reaction in
the immunologic test of that particular laboratory. Some researchers
have found "complete antibodies" (agglutinins, and lysins); others
have found "incomplete antibodies" (non-agglutinating and anti
globulin consuming); while some workers have failed to demonstrate
either type of anti-platelet factor in the sera of some patients
with UP. The study presented from this laboratory did not demon
strate by immune-adherence a "complete" or specific platelet anti
body in the sera from 10 patients with ITP. It is possible that an
auto-antibody went undetected, since homologous platelets were used.
However, a small number of experiments (not reported) were performed
using the patients own platelets as the antigen. These were also
negative. Six of our sera did give a weakly positive immune-ad
herence reaction when anti-globulin serum and platelets "sensitized"
in the test sera were used. For the moment these positive sera can
be considered to possess the "incomplete" type of anti-platelet
factor mentioned above.
Nature of "Platelet Antibody"
The various investigators, who have demonstrated an anti
platelet factor in UP and other diseases, have attempted to
classify and characterize such a serum component. Dausset (15)
considers that 5 types of platelet "antibody" have been demonstrated.
They are: l) the cold platelet agglutinins, which are active at 1;°C,
and are found in patients with cirrhosis, viral diseases and also
acute UP. They are non-specific pan-agglutinins for all plate
lets. 2) the warm platelet agglutinins - active only at 37°C, are
mainly iso-immune antibodies from multiple platelet transfusions.
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Dausset demonstrated warm agglutinins in 12 per cent of a large
series of non-thrombocytopenic patients who had been transfused.
He claimed that the discovery of these antibodies proved the
existence of platelet groups that are independent of the red cell
groups. Such platelet group incompatabilities may play a role in
some unexplained transfusion shock reactions (15).
3) the incomplete platelet antibodies - demonstrated by anti
globulin techniques, may be analogous to those of the immune
hemolytic anemias. They are found in some multiple transfusion
patients (iso-), and in some patients with UP who have never been
transfused (auto-).
k) the natural anti-A and anti-B antibodies for platelets -
identical with those for red cells. They represent a specific type
of cold agglutinins.
5) the allergic platelet antibodies - demonstrated in thrombocyto
penia to a drug hypersensitivity reaction.
Dausset (60) has extensively investigated the warm agglutinins
seen in patients who have had multiple transfusions. In I960 he
concluded that the warm agglutinin had the following characteristics.
"They react optimally at 37°G. and best at physiologic pH and ionic
strength; they are thermostable to heating at 56°C, They are in
hibited by a thermolabile factor that is probably complement, but
traces of complement enhance the reaction. They can cause platelet
lysis. They are present in the gamma globulin fraction of serum
proteins. The strongest
warm agglutinin can also be detected by tte




He assumed that they are probably immune iso-antibodies,
specific for toumans, which develop after a suitable stimulus (e.g.
transfusion and/or pregnancy). They did not react with the plate-
of the host, and reacted only with certain batches of platelets.
he feels certain that they are not related to any known red cell
antibodies, cold platelet agglutinins, or anti-platelet gamma glob
ulin substance detectable by the antiglobulin consumption test in
the serum of some cases of thrombocytopenic purpura, lupus erythem
atosus or pancytopenia. He concluded that their incidence in the
population in much less than for red cell antibodies, but never
theless these warm platelet agglutinins may be the cause of dimin
ished hemostatic effect of repeated platelet transfusions, of cer
tain transfusion reactions, and perhaps of some cases of thrombo
cytopenic purpura of the newborn (analogous to erythroblastosis
fetalis) .
Harrington (29) offers further reasons for assuming that the
platelet group agglutinins are not the same as red cell antibodies.
The transfusion of serum from a patient with UP producing thrmmbo-
cytopenia in a normal individual was done between red cell compatible
persons. Thrombocytopenia did not develop when normal ABO incompatible
blood was transfused into a normal recipient. Thirdly, thrombocyto
penia is rarely seen in hemolytic diseases of the newborn due to
Rh or ABO incompatibility. Also, in vitro, these warm platelet agg
lutinins were not affected by the ABO type of the platelet donor in
their agglutination reactions. It is possible that some agglutinins
are common to all platelets.
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Stefanini (5k) has also studied the nature of the platelet
agglutinin demonstrated by his technique in patients with chronic UP„
This agglutinin had the stable characteristics of a true antibody sim
ilar to the warm agglutinin studied by Dausset. However, Stefanini
found that his agglutinin was located in the beta2 globulin fraction
when the serum underwent electrophoresis, and not in the gamma glob
ulins.
The platelet lytic antibody studied by Tullis (68) was located
in the gamma globulin fraction on electrophoresis, however, his
patients with diseases of high concentrations of abnormal globulins
(e.g. multiple myeloma, lupus, macroglobulinemia, etc.,) did not
possess a platelet lytic antibody.
Lundevall (39) also concludes that platelet warm agglutinins,
although rare, are real antibodies as they are adsorbed by platelets
and can be eluted at a suitable temperature: they are probably active
in vivo.
Drug Purpura - An Experimental System
Drug hypersensitivity is a rare cause of thrombocytopenic pur
pura, however, an immunologic mechanism has been well demonstrated
in this disorder. The symptoms of this disease are identical to those
of UP. Many compounds have been responsible; the most commonly re
ported are: Sedormid, quinidine, arsenobenzols, and the sulfonamides
(72). Proof of a causal relationship is usually provided by obser
ving the recurrence of thrombocytopenic purpura in response to a
repeated dose of the drug after the patient has recovered from his
original attack. Treatment requires only that the administration of
the offending drug be stopped. Ackroyd (1,2) has studied the immunology
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of Sedormid purpura. The in vivo and in vitro techniques for dem
onstrating platelet antibodies in UP have proved that an antibody
is present in Sedormid purpura. Platelet agglutination, complement
fixation and other methods required the presence of the drug. Agg
lutination did not occur with cells other than platelets, and all
human platelets worked. Platelet lysis required four factors:
Sedormid, platelets, antibody and complement (2). Ackroyd (3)
theorized that Sedormid acting as a haptene united with platelets
to form the antigen. Because this linkage was easily broken, he
assumed that the platelet-Sedormid complex was weakly antigenic.
This may explain the rarity of this hypersensitivity phenomenon.
Shulman (51, 52, 53) has rigorously studied the immunology
and physical chemistry of quinidine purpura. He demonstrated the fix
ation of complement by an anti-bod^-quinidine-platelet complex.
The first step in the sequence appeared to be the combination of
quinidine with either antibody or platelets; but with which one
could not be determined. Based on the kinetics of the reaction, a
steric model was derived from which calculated theoretical results
equalled the experimental findings. The model consisted of two
platelet binding sites; one antibody, and two quinidine molecules:
this was the minimal requirement for the fixation of one complement
entity (5l). Ackroyd and others have suggested that the antigen in
drug purpura is a labile drug-platelet complex. According to Shulman,
this assumption makes it necessary to also assume that individuals
who develop sensitivity have a peculiar ability to form antibodies
against this weakly adsorbed hapten. Since he was unable to deter
mine if quinidine was first combined with platelet or antibody,
(both sequences satisfying
the theoretical equations) he postulated
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that the haptene and antibody were the first to combine. His exper
imental results were consistent with the possibilities that "the
protein moiety of a haptenic antigen involved in the development of
an antibody which attaches to a platelet is not necessarily a plate
let or a platelet component, and that the platelet reacts with the
antibody by virtue of having a surface favorable for non-specific
adsorption of certain haptene-antibody complexes" (51 )• The peculi
arity in this disease might then be the formation of a stable an
tigenic complex between a serlum protein and the drug (or an abnormal
metabolite of the drug). The possibility that certain antibodies
may interact non-specifically with receptive cellular membranes, and
in some instances thus injure the cell, is a theory of immuno-
hematologic disorders that deserves further study.
Pathogenesis of UP
Idiopathic thrombocytopenic purpura is a protean disease.
Studies by the investigators listed in Part I have shown that this
illness is characterized by a variable clinical course with spont
aneous remissions and relapses, and an inconstant response to splen
ectomy or the administration of adrenosteroids<> Discrepancies exist
between the degree of hemorrhagic manifestations and the level of
circulating platelets, and between the severity of the disease and
the presence of an in
vivo platelet agglutinin or an in vivo
thrombocytopenic fac tor.
Hypotheses concerning the role of megakaryocytes, platelets,
caoillaries, spleen, antobody, hormones, and their interactions in
the pathogenesis of UP have included the following possibilities
(53): a) Direct destruction
of platelets by a'lytic' antibody. This
is in agreement with in vitro studies, b) removal or sequestration of
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"sensitized" platelets by the spleen. This is the best explanation
for the rapid therapeutic effect of splenectomy, tiarrington has
demonstrated that platelet agglutinin levels were unchanged post
operatively, whereas the patient was much improved clinically.
c) destruction or suppression of megakaryocytes by antibody. This
idea is no longer popular. Izak and Nelken (3k) found no morph
ologic evidence of injury to the megakaryocytes when bone marrow
tissue cultures were incubated with an experimental ant ;.-platelet
serum or with serum from patients with chronic UP; platelet pro
duction was greatly accelerated in both cases, d) inhibition of
megakaryocyte maturation by a splenic hormone. This is doubtful.
It is more likely that the megakaryocytes are unable to keep up the
supply of platelets required by the circulation to counteract in
creased platelet destruction. The depleted megakaryocytes thus appear
immature, e) Production of anti-platelet antibodies by the spleen.
Since antibody formation occurs in lymphoid tissue, the spleen is
probably a major site, f) effect of antibodies or hormones on cap
illaries. The increased fragility of capillaries may be merely due
to deficient platelet hemostatic effectt, and not to an immune mech
anism. Shulman has shown that capillary endothelial cells do not react
with the antibody of quinidine thrombocytopenic purpura (5l).
Each or a combination of several of these possibilities may be
responsible for some cases of UP. This
variable disease may have
more than one pathogenic mechanism. Circumstantiated experimental
evidence supports the assumpation that an anti-platelet factor exists
in the blood of some patients with UP. When present, it may be a true
antibody in some cases or
a non-specific sensitizing globulin in others.
These demonstrated serum factors have been studied extensively,
however, comparatively little work has been done to determine the
ixact nature of the antigen and its specificity. It is here that the
studies of drug thrombocytopenia may be helpful. Ackroyd (3) believes
that the antigen in drug purpura is a haptene-platelet complex; while
Shulman (53) is in favor of a non-cellular antigen, namely a hap-
tene-3erum protein complex. These theories have also been suggested
for UP as follows.
It has been observed by numerous clinicians that the appearance
of acute UP, especially in a child, is preceded by several weeks
by a minor bacterial or viral infection, or some drug exposura, more
often than would be expected by chance. Kister and Stefanini (37)
suggested that some cases of UP may be almost identical to a drug
hypersensitivity thrombocytopenia with the modification that the
sensitizing agent may be a bacterial or viral product, instead of a
drug. They are in favor of Ackroyd 's haptene-platelet complex antigen
theory. In their experiments, rabbits were immunized with human
platelets previously modified by incubation in bacterial or viral
filtrates or drug solutions. Intravenous injection of the specific
modifying agent (haptene) used produced thromboytopenia of 1 to 3 day's
duration, and complement finxing antibodies
in the presence of the
modifier and platelets were demonstrated. They also found platelet
auto- and iso-antibodies when modifying agent plus the animals' own un
treated platelets were injected through different veins (6l). No good
explanation was offered for these results, however, Stefanini suggests
a similar situation may occur in man when infection is present.
Shulman (53) offers a stimulating interpretation of the pathogen-
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esis of UP based on his antigen theory for drug purpura. He states
that antigenic stimuli in UP could be simple molecules (haptenes)
which are ingested, formed metabolicaily, or produced by infectious
agents, in which case antibody against the haptene-serum protein
complex may combine with this antigen, and then adhere to the surface
of platelets producing a deleterious effect. "It would be possible,
however, for the antigen to be a protein molecule without an assoc
iated haptene, the antigen being adsorbed by platelets in combination
with the antibody it provokes." This possibility is suggested by
observations of Miescher and Straessle (liL) concerning the agglutin
ation or damage of platelets by non-related antigen-antibody complexes.
Shulman' s theory could account for the variable picture of UP being
due to variations in the degree and persistence of antibody response
or in the relative concentration of haptene (or other types of anti
gen). In chronic UP, effective antigenic stimulus would be per
sistent, and in acute ITP transient. Antigen and antibody com
plexes with platelets would no doubt differ in individual cases; and
it would be impossible to predict in each case whether the amounts
of adsorbed antibody, although sufficient to produce thromboctyo-
penia, would necessarily give positive in vitro immunologic tests;
or whether, measurable in vitro effects would necessarily be as
sociated with thrombocytopenia. With this theory, splenectomy would
be therapeutic by removing the major site of platelet sequestra
tion, but it would not affect
the underlying basis of the disease.
Steroid therapy may have a direct effect on the antigen-antibody
gystem resulting
in decreased antibody formation, or it may inter
fere with cell-antibody union. Cortisone may increase platelet.pro
duction as well. Shulman has presented a unitary concept for the
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pathogenesis of a group of diseases characterized by primary
thrombocytopenia (53).
The author's experiments did not demonstrate a true platelet
antibody in the 10 patients with UP tested. Based on the reli
ability of the immune-adherence technique to detect antibody for
particulate antigen, it is doubtful that a specific antibody against
platelets exists in this disease. There is no reason to suspect
that a antibody for a non-cellular antigen (as suggested by
Shulman) would be detected in immune-adherence with platelets,
even if such a protein-haptene antigen was present in the
patients' serum. The low titer platelet-coating globulin, that
was demonstrated in the sera from 6 of the 7 acute cases of UP,
cannot be considered to be a true antibody. It is probably the
same substance that has been called "incomplete", "non-agglutinat
ing", and "blocking" antibody by investigators who have detected
it with other anti-globulin serum techniques. The pertinent
question: whether this globulin is responsible for the thrombo
cytopenia cannot be answered at this time. It may represent a
disarrangement of the body's normal globulin spectrum in response
to a primary disease, as is observed in diseases where the total
serum globulin concentration is elevated. The presence of this
platelet-coating globulin in UP may be similar to the persistent
appearance of non-specific cold platelet agglutinins. in cirrhosis,
carcinomatosis, and the dysproteinemias and their transient
duration in viral diseases and post-innoculation states. The
significance of either of these two types of serum factors is not
known.
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In conclusion, it must be stated that although some cases
of UP display serologic anti-platelet manifestations, a unified
immunologic etiology for this disease has never been demonstrated.
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SUMMARY
1. Evidence implicating the existence of an anti-platelet
factor in the serum of patients with idiopathic thrombocytopenic
purpura has been reviewed. The transfusion of UP serum has pro
duced thrombocytopenia in normal recipients, and normal platelets
transfused into patients with this disease are rapidly destroyed.
Several laboratories have demonstrated in vitro anti-platelet
factors in variable percentages of UP cases. Platelet group
antigen incompatibility may possibly be responsible for some
cases of neonatal thrombocytopenic purpura and transfusion
reactions.
2. Anti-human platelet serum was produced in rabbits, and
was demonstrated in high titer by immune-adherence, in the
presence of either human or guinea pig complement. Serum from
ten patients with UP did not show immune-adherence for platelet
antigen. Normal platelets previously incubated with UP serum
demonstrated immune -adherence when anti-human globulin serum was
used as antibody. This platelet-coating globulin was present in
six of the cases; it cannot be characterized as a true antibody,
and may resemble abnormal globulins found in dysprotenemic diseases.
3. A recent non-platelet antigen theory for UP is discussed.
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